UBE2C and breast carcinoma: In breast cancer, while upregulation of UBE2C promotes drug resistance, knockdown of UBE2C sensitizes the cells to radiation and chemotherapeutic drugs, such as tamoxifen, doxorubicin, epirubicin, and docetaxel [83,84].